CD19 is a major B cell receptor–independent activator of MYC-driven B-lymphomagenesisElaine Y. Chung, Andrei Thomas‐Tikhonenko|Journal of Clinical Investigation|2012Cited by 95
Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapiesZhiwei Ang, Andrei Thomas‐Tikhonenko|Blood|2023Cited by 43
Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphomaColleen T. Harrington, Andrei Thomas‐Tikhonenko|Leukemia|2019Cited by 29
An Alternatively Spliced Gain-of-Function NT5C2 Isoform Contributes to Chemoresistance in Acute Lymphoblastic LeukemiaManuel Torres-Diz, Andrei Thomas‐Tikhonenko|Cancer Research|2024Cited by 10
MYC hyperactivates WNT signaling in APC/CTNNB1-mutated colorectal cancer cells through miR-92a-dependent repression of DKK3Priyanka Sehgal, Andrei Thomas‐Tikhonenko|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 0